# A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

> **NCT06051409** · PHASE3 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 350 (estimated)

## Conditions studied

- Ph+ ALL
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

## Interventions

- **DRUG:** Olverembatinib
- **DRUG:** Investigator's choice of TKI

## Key facts

- **NCT ID:** NCT06051409
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-06-30
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06051409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06051409, "A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06051409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*